The
dosing schedule for RotaTeq aligns with well-baby visits
at 2, 4, and 6 months of age.
The safety and efficacy of
RotaTeq have not been established in infants less than
6 weeks of age or greater than 32 weeks of age.
Select safety
information
In clinical trials, RotaTeq was routinely administered
concomitantly with diphtheria and tetanus toxoids and
acellular pertussis (DTaP), inactivated poliovirus
vaccine (IPV), H. influenzae type b conjugate vaccine (Hib), hepatitis B
vaccine, and pneumococcal conjugate vaccine.
There was no
evidence for reduced antibody responses to the diphtheria
or tetanus toxoid components of DTaP or to the other vaccines
that were concomitantly administered with RotaTeq. However,
insufficient immunogenicity data are
available to confirm lack of interference of immune responses when RotaTeq
is concomitantly
administered with childhood vaccines to prevent pertussis.
